Phase 2 HER2-negative Breast Cancer trials recruiting now

All HER2-negative Breast Cancer trials, every phase

Other phases for HER2-negative Breast Cancer

Phase 2 HER2-negative Breast Cancer trials

• A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
  NCT06568692 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer
  NCT07483307 · Phase: Phase 2 · Ages: 50 Years and older · Sex: Female · 7 locations
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
  NCT05824975 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
  NCT04985266 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 49 locations
• Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
  NCT05660083 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
  NCT05524584 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
  NCT06176261 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
  NCT07198724 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
  NCT04576143 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
  NCT05982093 · Phase: Phase 2 · Ages: 35 Years and older · Sex: Female · 15 locations
• Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
  NCT04573231 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
  NCT05305924 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
  NCT01042379 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 42 locations
• Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
  NCT06953882 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study
  NCT07602907 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
  NCT06516289 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Organoid-based Functional Precision Therapy for Advanced Breast Cancer
  NCT06102824 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• PRE-ISPY Phase I/II Oncology Platform Program
  NCT05868226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
  NCT06649331 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Reverse HER2-negative Immune Resistant Breast Cancer
  NCT06731140 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
  NCT05467891 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• SNF Platform Study of HR+/ HER2-advanced Breast Cancer
  NCT05594095 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Sacituzumab Govitecan In TNBC
  NCT04230109 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
  NCT07396454 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 154 locations
• Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
  NCT06518837 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
  NCT06970912 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.